Subject(s)
Lung Neoplasms/complications , Pulmonary Atelectasis/etiology , Ultrasonography , Adenocarcinoma/complications , Adenocarcinoma/diagnosis , Aged , Carcinoma, Small Cell/complications , Carcinoma, Small Cell/diagnosis , Carcinoma, Squamous Cell/complications , Carcinoma, Squamous Cell/diagnosis , Female , Humans , Lung Neoplasms/diagnosis , Middle Aged , Pulmonary Atelectasis/diagnosisSubject(s)
Blood Proteins/analysis , Ethnicity , Adult , Aged , California , Female , Hawaii , Humans , Japan/ethnology , Male , Middle AgedABSTRACT
A case of mediastinal liposarcoma in a 45-year-old man is reported. The patient was admitted to the hospital complaining of rhinorrhea. A large mass was found in the right thorax by chest X-ray. At thoracotomy, a tumor measuring 11.5 X 9 X 8.5 cm located in the anterior mediastinum with an extension to the pleural cavity formed in right middle and lower lobes was found and removed from the adjacent visceral pleura. The tumor had a fibrous capsule and was multinodular in external appearance. The cut surface was yellowish and gelatinous. The histological diagnosis of myxoid liposarcoma was made according to the subclassification of liposarcoma proposed by Enzinger et al.
Subject(s)
Liposarcoma/pathology , Mediastinal Neoplasms/pathology , Humans , Liposarcoma/surgery , Male , Mediastinal Neoplasms/surgery , Middle AgedSubject(s)
Lung Neoplasms/complications , Pulmonary Fibrosis/complications , Adenocarcinoma/complications , Adenocarcinoma/immunology , Aged , Carcinoma, Small Cell/complications , Carcinoma, Small Cell/immunology , Carcinoma, Squamous Cell/complications , Carcinoma, Squamous Cell/immunology , Female , Humans , Lung Neoplasms/immunology , Male , Middle Aged , Pulmonary Fibrosis/immunologyABSTRACT
A total of 36 cases with small cell carcinoma of the lung were treated with Ifosfamide. Fourteen cases (38.9%) out of 36 cases showed good or marked clinical response, and 120 mg/kg of Ifosfamide was necessary as a minimum dose to obtain effective response. As side effects of Ifosfamide, gastrointestinal disturbance (66.7%), depilation (66.7%), leukopenia (38.9%) and hematuria (36.1%) were observed. Mean survival time (M.S.T.) was prolonged by using Ifosfamide, comparing with the groups treated by with other anticancer drugs. Ifosfamide, therefore, should be used for the treatment of small cell carcinoma of the lung.